S. Xiong

816 total citations
15 papers, 635 citations indexed

About

S. Xiong is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, S. Xiong has authored 15 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 9 papers in Hepatology and 5 papers in Infectious Diseases. Recurrent topics in S. Xiong's work include Hepatitis B Virus Studies (9 papers), Hepatitis C virus research (9 papers) and Liver Disease Diagnosis and Treatment (5 papers). S. Xiong is often cited by papers focused on Hepatitis B Virus Studies (9 papers), Hepatitis C virus research (9 papers) and Liver Disease Diagnosis and Treatment (5 papers). S. Xiong collaborates with scholars based in China, Macao and United States. S. Xiong's co-authors include Carol Brosgart, Mark Sullivan, K. Kleber, DF Gray, Kris V. Kowdley, Peter Buggisch, Marc Bourlière, E. Jenny Heathcote, Ramin Ebrahimi and R Rubin and has published in prestigious journals such as Gastroenterology, Journal of Hepatology and Frontiers in Pharmacology.

In The Last Decade

S. Xiong

14 papers receiving 619 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Xiong China	7	606	585	144	18	11	15	635
Eirum Chaudhri Japan	3	437 0.7×	509 0.9×	113 0.8×	26 1.4×	7 0.6×	3	531
T. Santantonio Italy	8	656 1.1×	677 1.2×	74 0.5×	11 0.6×	5 0.5×	17	709
Zayani Sims United States	7	332 0.5×	373 0.6×	69 0.5×	24 1.3×	3 0.3×	10	401
Shigeru Yotsumoto Japan	8	382 0.6×	372 0.6×	60 0.4×	11 0.6×	16 1.5×	11	415
A.R. Türkyilmaz Türkiye	9	368 0.6×	359 0.6×	67 0.5×	14 0.8×	14 1.3×	15	394
Tuan Nguyen United States	9	516 0.9×	519 0.9×	120 0.8×	70 3.9×	15 1.4×	16	611
Cecilia Marrocco Italy	11	454 0.7×	466 0.8×	65 0.5×	9 0.5×	9 0.8×	15	500
Michèle Martinot France	9	418 0.7×	419 0.7×	57 0.4×	13 0.7×	5 0.5×	15	461
Annika Kau Germany	3	371 0.6×	372 0.6×	43 0.3×	9 0.5×	5 0.5×	4	410
Watcharasak Chotiyaputta Thailand	13	555 0.9×	546 0.9×	106 0.7×	22 1.2×	11 1.0×	30	623

Countries citing papers authored by S. Xiong

Since Specialization

Citations

This map shows the geographic impact of S. Xiong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Xiong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Xiong more than expected).

Fields of papers citing papers by S. Xiong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Xiong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Xiong. The network helps show where S. Xiong may publish in the future.

Co-authorship network of co-authors of S. Xiong

This figure shows the co-authorship network connecting the top 25 collaborators of S. Xiong. A scholar is included among the top collaborators of S. Xiong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Xiong. S. Xiong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Guo, Jin, S. Xiong, Xinyuan Zhang, et al.. (2025). Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. Pharmaceuticals. 18(4). 511–511.

Ji, Teng, et al.. (2025). Ferroptosis enhances the therapeutic potential of oncolytic adenoviruses KD01 against cancer. Cancer Gene Therapy. 32(4). 403–417. 4 indexed citations

Dai, Zhou‐Tong, et al.. (2025). Chimeric Ad5/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency. Cancer Gene Therapy. 32(4). 418–436. 3 indexed citations

Li, Bo, Wei Meng, S. Xiong, et al.. (2024). Phloretic acid requires the insulin/IGF-1 pathway and autophagy to enhance stress resistance and extend the lifespan of Caenorhabditis elegans. Frontiers in Pharmacology. 15. 1384227–1384227. 2 indexed citations

Xiong, S., Gui-Sheng Wu, Chun Li, Wenzhe Ma, & Huai‐Rong Luo. (2024). Clinical efficacy of probiotics in the treatment of alcoholic liver disease: a systematic review and meta-analysis. Frontiers in Cellular and Infection Microbiology. 14. 1358063–1358063. 15 indexed citations

Gu, Long, S. Xiong, Guisheng Wu, et al.. (2024). Serum liver enzymes and risk of stroke: Systematic review with meta‐analyses and Mendelian randomization studies. European Journal of Neurology. 31(12). e16506–e16506. 4 indexed citations

Westland, C., Hao Yang, William E. Delaney, et al.. (2005). Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients. Journal of Viral Hepatitis. 12(1). 67–73. 54 indexed citations

Qi, Xiaole, Vincent Thibault, Yefei Zhu, et al.. (2004). 57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. Journal of Hepatology. 40. 20–20. 39 indexed citations

Yang, Hao, Xiaole Qi, Kalyan Das, et al.. (2004). 382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase. Journal of Hepatology. 40. 114–114. 17 indexed citations

10.

Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations

11.

Xiong, S., C. Westland, William E. Delaney, et al.. (2003). Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 182–182. 35 indexed citations

12.

Neumann, Avidan U., Manuel Tsiang, Michael Wulfsohn, et al.. (2003). Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 26–26. 3 indexed citations

13.

Westland, C., William E. Delaney, Vincent Thibault, et al.. (2003). Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy. Journal of Hepatology. 38. 182–182. 6 indexed citations

14.

Yang, Hao, S. Xiong, & William E. Delaney. (2003). Efficient in vitro phenotypic analysis of full lengrh clinical HBV isolates using a novel expression vector. Journal of Hepatology. 38. 8–8. 1 indexed citations

15.

Schiff, Eugene R., P. Neuhaus, Didier Samuel, et al.. (2002). Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. Journal of Hepatology. 36. 32–32. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact